Heron Therapeutics (HRTX)
1.7900 +0.0600 (+3.47%) 12:40 ET [NASDAQ]
1.7800 x 986 1.8000 x 1200
Realtime by (Cboe BZX)
1.7800 x 986 1.8000 x 1200
Realtime 1.7300 unch (unch) 08:53 ET
for Mon, Feb 24th, 2025
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
Assets | |||||
Current Assets | |||||
Cash & Cash Equivalents | 28,677 | 15,364 | 90,541 | 105,138 | 71,898 |
Marketable Securities | 51,732 | 69,488 | 67,039 | 103,353 | 319,074 |
Receivables | 60,137 | 52,049 | 35,499 | 41,850 | 39,879 |
Inventories | 42,110 | 54,573 | 48,382 | 41,905 | 24,968 |
TOTAL | $188,774 | $205,435 | $254,423 | $314,196 | $479,064 |
Non-Current Assets | |||||
PPE Net | 20,166 | 22,160 | 23,734 | 22,737 | 19,618 |
Other Non-Current Assets | 13,566 | 23,356 | 27,549 | 16,623 | 14,100 |
TOTAL | $33,732 | $45,516 | $51,283 | $39,360 | $33,718 |
Total Assets | $222,506 | $250,951 | $305,706 | $353,556 | $512,782 |
Liabilities | |||||
Current Liabilities | |||||
Accounts payable and accrued liabilities | 3,240 | 3,225 | 3,803 | 525 | 2,758 |
Accrued Expenses | 31,515 | 37,884 | 38,979 | 63,559 | 49,862 |
TOTAL | $79,685 | $82,355 | $71,058 | $102,503 | $96,705 |
Non-Current Liabilities | |||||
Long Term Debt | 24,263 | N/A | N/A | N/A | N/A |
aiOther Non-Current Liabilities | 152,531 | 155,024 | 157,078 | 14,561 | 12,242 |
TOTAL | $176,794 | $155,024 | $157,078 | $14,561 | $12,242 |
Total Liabilities | $256,479 | $237,379 | $228,136 | $117,064 | $108,947 |
Shareholders' Equity | |||||
Shares Outstanding, K | 150,329 | 119,259 | 102,141 | 91,397 | 90,374 |
Common Shares | 1,503 | 1,191 | 1,020 | 913 | 903 |
Retained earnings | -1,906,014 | -1,795,455 | -1,613,431 | -1,392,748 | -1,165,470 |
Other shareholders' equity | 13 | -19 | -6 | 257 | 85 |
TOTAL | $-33,973 | $13,572 | $77,570 | $236,492 | $403,835 |
Total Liabilities And Equity | $222,506 | $250,951 | $305,706 | $353,556 | $512,782 |